Skip to main content

COEP

Stock

COEP

Stock
Health Care
Biotechnology

Performance overview

COEP Price
Price Chart

Forward-looking statistics

Beta
0.31
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

SectorHealth Care
IndustryBiotechnology
Employees7
Market cap$10.4M

Fundamentals

Enterprise value$26.2M
Revenue$62.9K
Revenue per employee
Profit margin0.00%
Debt to equity27.34

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$6.13
Dividend per share$0.42
Revenue per share$0.03
Avg trading volume (30 day)$292K
Avg trading volume (10 day)$382K
Put-call ratio

Macro factor sensitivity

Growth-8.0
Credit+19.4
Liquidity+9.6
Inflation-8.3
Commodities-7.5
Interest Rates-5.9

Valuation

Dividend yield5.57%
PEG Ratio-44.35
Price to sales421.39
P/E Ratio-44.35
Enterprise Value to Revenue416.14
Price to book3.92

Upcoming events

Next earnings dayNovember 9, 2023
Next dividend day
Ex. dividend dayJuly 18, 2022

News

This SPAC is merging with an already-public company as sponsors get creative before time runs out

Many sponsors face challenges as they race the clock to find a target amid regulatory crackdown and waning enthusiasm.

CNBC (June 9, 2022)
Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform

Coeptis Therapeutics Inc (OTC: COEP) has entered into a strategic agreement with Statera Biopharma Inc (NASDAQ: STAB) that gives Coeptis the right to acquire Statera'stoll-like receptor 5 (TLR5) agonist platform, including entolimod.  Coeptis will agree to pay.

Benzinga (April 13, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free